Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to measure the impact of these new therapies and diagnostic techniques in clinical practice.
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 4,000 people at 3 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
Primary outcome (registry wording): Change from baseline in the Korean Mini-Mental State Examination-2 (K-MMSE-2) total score
Who it is for (from inclusion criteria)
Ages 19 Years to any
Patients who have undergone an amyloid PET scan to confirm Alzheimer's disease pathology, or cerebrospinal fluid testing for Aβ42 and ptau181
Clinical diagnosis of Alzheimer's disease, defined as follows:
\[Alzheimer's Disease Dementia (ADD)\] - Must meet the criteria for probable Alzheimer's dementia as defined by the National Institute on Aging and the Alzheimer's Association working groups (NIA-AA)
Must exhibit cognitive decline that impairs independent daily living
\[Mild Cognitive Impairment (MCI)\]
\- Must meet NIA-AA diagnostic criteria for MCI
\- The subject or informant must report cognitive decline
Who the registry excludes
Presence of significant psychiatric disorders associated with intellectual disability, schizophrenia, major depression, bipolar disorder, delirium, etc
History of substance abuse or alcohol dependence that required treatment within the past five years
A current diagnosis of cancer that has not achieved remission within the past five years. However, localized prostate cancer, cervical carcinoma in situ, non-melanoma skin basal cell carcinoma, or squamous cell carcinoma are excluded
Evidence of severe or unstable physical conditions (e.g., dialysis, severe liver disease)
Visual or auditory impairments that prevent the satisfactory assessment of cognitive function
Inability to perform MRI due to the presence of metallic substances in the body
Currently participating in another drug clinical trial
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06889818?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06889818?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.